A huge extrarenal cell carcinoma developing from a heterotopic renal anlage with distant metastases: case report and literature review.

J Surg Case Rep

Department of General Surgery, Faculty of Medicine, Al Assad University Hospital, Damascus University, Damascus, Syria.

Published: August 2020

Renal cell carcinoma (RCC) is the most common type of renal tumor arising from the proximal renal tubules. Extrarenal RCC is a rare case in which a tumor is found outside the kidney with no primary kidney tumor. Some theories suggest that these tumors arise from mesoderm remnant. Here, we present a unique case, the fourth in literature, of peri-renal, Extrarenal RCC case and the first case with a huge mass with distant metastases and aggressive progression.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7442920PMC
http://dx.doi.org/10.1093/jscr/rjaa227DOI Listing

Publication Analysis

Top Keywords

cell carcinoma
8
distant metastases
8
extrarenal rcc
8
case
5
huge extrarenal
4
extrarenal cell
4
carcinoma developing
4
developing heterotopic
4
renal
4
heterotopic renal
4

Similar Publications

Grading systems and perineural invasion in oral squamous cell carcinoma - a disease-specific survival analysis.

Med Oral Patol Oral Cir Bucal

January 2025

Department of Oral Diagnosis, Piracicaba Dental School University of Campinas, 901, Limeira Avenue Postcode: 13414-903. Piracicaba-SP, Brazil

Background: Oral squamous cell carcinoma (OSCC) is an aggressive cancer, with prognosis influenced by clinical variables as well grading systems and perineural invasion (PNI), which are associated to poorer outcomes, including higher rates of recurrence and metastasis. This study aims to evaluate OSCC using three grading systems and assess the impact of PNI and clinicopathologic parameters on patient survival.

Material And Methods: Eighty-one primary OSCC samples were analyzed.

View Article and Find Full Text PDF

Significance of adding chemotherapy to radiotherapy in the treatment of T2N0 glottic cancer.

Jpn J Clin Oncol

January 2025

Department of Otorhinolaryngology, Head and Neck Surgery, Yokohama City University, School of Medicine, Yokohama, Japan.

The prognosis for T2N0 glottic squamous cell carcinoma (SCC) is generally favorable, with a 5-year overall survival rate of 79%-96% achieved with radiotherapy (RT), the standard nonsurgical treatment for this condition. However, the local control rate for T2N0 glottic SCC treated with RT remains suboptimal, with a 5-year local control rate of only 65%-80%. Local residual disease or recurrence following RT for T2N0 glottic SCC often leads to difficulties in laryngeal preservation.

View Article and Find Full Text PDF

This study aims to investigate the expression of seven cancer testis antigens (MAGE-A1, MAGE-A4, MAGE-A10, MAGE-A11, PRAME, NY-ESO-1 and KK-LC-1) in pan squamous cell carcinoma and their prognostic value, thus assessing the potential of these CTAs as immunotherapeutic targets. The protein expression of these CTAs was evaluated by immunohistochemistry in 60 lung squamous cell carcinoma (LUSC), 62 esophageal squamous cell carcinoma (ESCA) and 62 head and neck squamous cell carcinoma (HNSC). The relationship between CTAs expression and progression-free survival (PFS) was assessed.

View Article and Find Full Text PDF

We demonstrate that performing anatomical pulmonary resection by video-assisted thoracoscopic surgery without staplers or energy devices is feasible. This technique is an alternative for surgeons with limited access to expensive technologies.

View Article and Find Full Text PDF

Introduction: Complete radical resection is crucial for successfully treating thymic carcinomas. However, when the invasion of the great vessels or the heart in Masaoka III and IV stages occurs, the management poses more challenges. The R0 resection often requires neoadjuvant treatment.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!